- Home
- NVNI vs BTAI Comparison
NVNI vs BTAI Comparison
Compare NVNI & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVNI | BTAI |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NVNI | BTAI |
|---|---|---|
| Price | $3.13 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 160.4K | ★ 544.2K |
| Earning Date | 09-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,250,627.00 | $752,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $15.02 | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1491.58 | N/A |
| 52 Week Low | $1.44 | $1.17 |
| 52 Week High | $121.90 | $9.26 |
Technical Indicators
Market Signals| Indicator | NVNI | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 44.03 |
| Support Level | $3.32 | $1.82 |
| Resistance Level | $3.92 | $2.30 |
| Average True Range (ATR) | 0.36 | 0.17 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 23.57 | 11.78 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.